Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Apogee Therapeutics Inc’s stock clocked out at $37.24, down -1.35% from its previous closing price of $37.75. In other words, the price has decreased by -$1.35 from its previous closing price. On the day, 0.53 million shares were traded. APGE stock price reached its highest trading level at $38.305 during the session, while it also had its lowest trading level at $37.13.
Ratios:
To gain a deeper understanding of APGE’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.82 and its Current Ratio is at 15.82. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on July 07, 2025, Reiterated its Buy rating but revised its target price to $115 from $100 previously.
On March 13, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $95.
On November 25, 2024, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $89.Canaccord Genuity initiated its Buy rating on November 25, 2024, with a $89 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 02 ’25 when Dambkowski Carl sold 10,090 shares for $45.09 per share. The transaction valued at 454,954 led to the insider holds 238,998 shares of the business.
CARL DAMBKOWSKI bought 22,345 shares of APGE for $988,990 on Jul 02 ’25. On Jun 04 ’25, another insider, Dambkowski Carl, who serves as the Chief Medical Officer of the company, sold 2,725 shares for $36.96 each. As a result, the insider received 100,716 and left with 241,723 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APGE now has a Market Capitalization of 2171565056 and an Enterprise Value of 1672142336.
Stock Price History:
The Beta on a monthly basis for APGE is 1.46, which has changed by -0.10802394 over the last 52 weeks, in comparison to a change of 0.20799685 over the same period for the S&P500. Over the past 52 weeks, APGE has reached a high of $63.50, while it has fallen to a 52-week low of $26.20. The 50-Day Moving Average of the stock is -6.95%, while the 200-Day Moving Average is calculated to be -10.63%.
Shares Statistics:
It appears that APGE traded 903.24K shares on average per day over the past three months and 613560 shares per day over the past ten days. A total of 46.04M shares are outstanding, with a floating share count of 37.32M. Insiders hold about 37.32% of the company’s shares, while institutions hold 88.18% stake in the company. Shares short for APGE as of 1752537600 were 9192676 with a Short Ratio of 10.18, compared to 1749772800 on 9175746. Therefore, it implies a Short% of Shares Outstanding of 9192676 and a Short% of Float of 33.57.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Apogee Therapeutics Inc (APGE) is presently subject to a detailed evaluation by 5.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$1.09, with high estimates of -$0.89 and low estimates of -$1.32.
Analysts are recommending an EPS of between -$3.55 and -$4.94 for the fiscal current year, implying an average EPS of -$4.3. EPS for the following year is -$4.86, with 5.0 analysts recommending between -$3.83 and -$6.32.
